Stay on the Cutting Edge of Biotech, MedTech, and Pharma.
100% free, unsubscribe anytime.
Amgen named no dates at Morgan Stanley, Scholar Rock's price came out two ways, the FDA approved the first Lutathera equivalent, and Monday's readout winners gave it back.
The FDA approved Scholar Rock's Isembyld 19 days before its action date, AstraZeneca printed a PFS win beside a survival question at WCLC, two B7-H3 ADCs posted the same hazard ratio, and Definium went three for three in anxiety.
AstraZeneca's SERENA-4 missed eight days after Etcamah's approval, WCLC put an 18.5 month small cell survival number on the board, SK put dates and conditions on the Biohaven close, and two long open items resolved on primary documents.
The FDA paused Biohaven's pivotal epilepsy enrollment fifteen days after its up to $795M SK deal, an Artisan Partners manager demanded Novartis board changes, Axogen paid $200M for sutureless nerve repair, and the surrogate discount week closed with nothing round tripped.
BMS' arlo-cel cleared its pivotal myeloma trial with the data held for a congress, Bayer's Hyrnuo won first line lung cancer approval on a 75% response rate, the FDA's drug and biologics chiefs went permanent, and three private rounds raised $550 million in a day.
Del-desiran failed its Phase 3 with the numbers withheld, Amgen dropped 10.1% on Lp(a) readacross despite an Imdelltra survival win, the FDA approved Etcamah over its advisers' no vote, and Boston Scientific told the SEC its guidance is out of reach.
